Brief: Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up

Travere Therapeutics

26/09/2024 21:04

Sept 26 (Reuters) - Travere Therapeutics Inc  TVTX.O :
    * TRAVERE THERAPEUTICS ANNOUNCES VOLUNTARY PAUSE OF
ENROLLMENT IN
THE PHASE 3 HARMONY STUDY OF PEGTIBATINASE RELATED TO COMMERCIAL
MANUFACTURING SCALE-UP
    * TRAVERE THERAPEUTICS INC - PAUSE TO ADDRESS MANUFACTURING
SCALE-UP PROCESS IMPROVEMENTS
    * TRAVERE THERAPEUTICS INC - ENROLLMENT IN PHASE 3 HARMONY
STUDY
EXPECTED TO RESTART IN 2026
    * TRAVERE THERAPEUTICS INC - INVESTMENTS IN HARMONY
ENROLLMENT AND
PRODUCTION DELAYED BEYOND 2025
    * TRAVERE THERAPEUTICS INC - RESEARCH AND DEVELOPMENT
EXPENSES
EXPECTED TO BE REDUCED BY MORE THAN $30 MILLION IN 2025
    * TRAVERE THERAPEUTICS INC - CURRENTLY ENROLLED PATIENTS TO
CONTINUE RECEIVING STUDY MEDICATION

Source text for Eikon:  ID:nGNX10KkQ4 
Further company coverage:  TVTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))